AR097971A1 - Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas - Google Patents

Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas

Info

Publication number
AR097971A1
AR097971A1 ARP140103759A ARP140103759A AR097971A1 AR 097971 A1 AR097971 A1 AR 097971A1 AR P140103759 A ARP140103759 A AR P140103759A AR P140103759 A ARP140103759 A AR P140103759A AR 097971 A1 AR097971 A1 AR 097971A1
Authority
AR
Argentina
Prior art keywords
formula
compound represented
appear
diffraction pattern
powder diffraction
Prior art date
Application number
ARP140103759A
Other languages
English (en)
Spanish (es)
Inventor
Abe Takao
Furuuchi Takeshi
Sakamaki Yoshiaki
Mitsuhashi Nakako
Saito Yumiko
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AR097971A1 publication Critical patent/AR097971A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP140103759A 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas AR097971A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08

Publications (1)

Publication Number Publication Date
AR097971A1 true AR097971A1 (es) 2016-04-20

Family

ID=52813113

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP140103759A AR097971A1 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
ARP240100516A AR132029A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100517A AR132030A2 (es) 2013-10-08 2024-03-01 Proceso de producción de formas cristalinas de derivado de diazabiciclooctano
ARP240100515A AR132028A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP240100516A AR132029A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100517A AR132030A2 (es) 2013-10-08 2024-03-01 Proceso de producción de formas cristalinas de derivado de diazabiciclooctano
ARP240100515A AR132028A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida

Country Status (22)

Country Link
US (5) US10131665B2 (cg-RX-API-DMAC7.html)
EP (4) EP3613740A1 (cg-RX-API-DMAC7.html)
JP (3) JP6617029B2 (cg-RX-API-DMAC7.html)
KR (2) KR102388529B1 (cg-RX-API-DMAC7.html)
CN (2) CN105612159A (cg-RX-API-DMAC7.html)
AR (4) AR097971A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014332960B2 (cg-RX-API-DMAC7.html)
BR (2) BR122022016622B1 (cg-RX-API-DMAC7.html)
CA (2) CA3110803C (cg-RX-API-DMAC7.html)
DK (1) DK3067355T3 (cg-RX-API-DMAC7.html)
ES (2) ES2901198T3 (cg-RX-API-DMAC7.html)
HK (1) HK1219479A1 (cg-RX-API-DMAC7.html)
HU (1) HUE051925T2 (cg-RX-API-DMAC7.html)
IL (2) IL244969B (cg-RX-API-DMAC7.html)
MX (2) MX383661B (cg-RX-API-DMAC7.html)
MY (1) MY199066A (cg-RX-API-DMAC7.html)
NZ (5) NZ719568A (cg-RX-API-DMAC7.html)
RU (1) RU2695219C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201602723RA (cg-RX-API-DMAC7.html)
TW (1) TWI673269B (cg-RX-API-DMAC7.html)
WO (1) WO2015053297A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602054B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
DK3050883T3 (da) * 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
SG11201704576SA (en) * 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
KR20200030584A (ko) 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
KR20200091395A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
EP3687504B1 (en) 2017-09-27 2024-11-27 Meiji Seika Pharma Co., Ltd. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
TW201920174A (zh) 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
CN119707784A (zh) * 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
WO2022014395A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (cg-RX-API-DMAC7.html) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (cg-RX-API-DMAC7.html) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
US6111098A (en) 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) * 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8829191B2 (en) * 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
ES2672100T3 (es) * 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
DK3050883T3 (da) * 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
IN2014MU01192A (cg-RX-API-DMAC7.html) 2014-03-29 2015-10-02 Wockhardt Ltd
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation

Also Published As

Publication number Publication date
CA2926071A1 (en) 2015-04-16
RU2016116501A (ru) 2017-11-15
EP3067355A1 (en) 2016-09-14
HK1219479A1 (zh) 2017-04-07
ZA201602054B (en) 2019-06-26
US20220348578A1 (en) 2022-11-03
CA3110803C (en) 2022-09-27
CA2926071C (en) 2021-11-09
AU2014332960B2 (en) 2018-03-29
WO2015053297A1 (ja) 2015-04-16
CN105612159A (zh) 2016-05-25
JP6995810B2 (ja) 2022-01-17
NZ757222A (en) 2021-12-24
MX361659B (es) 2018-12-13
EP3613740A1 (en) 2020-02-26
IL244969A0 (en) 2016-05-31
KR102388529B1 (ko) 2022-04-20
JP7182677B2 (ja) 2022-12-02
US20200181143A1 (en) 2020-06-11
US20250059191A1 (en) 2025-02-20
US12221443B2 (en) 2025-02-11
EP3299370B1 (en) 2021-11-24
EP3299370A1 (en) 2018-03-28
SG11201602723RA (en) 2016-05-30
IL289275B2 (en) 2023-02-01
AU2014332960A1 (en) 2016-05-26
US10604522B2 (en) 2020-03-31
ES2901198T3 (es) 2022-03-21
JP2021193107A (ja) 2021-12-23
EP3067355B1 (en) 2020-12-16
IL289275B (en) 2022-10-01
NZ743374A (en) 2021-12-24
MX383661B (es) 2025-03-14
TW201605855A (zh) 2016-02-16
KR20160065871A (ko) 2016-06-09
NZ719568A (en) 2018-06-29
US20190031659A1 (en) 2019-01-31
RU2695219C2 (ru) 2019-07-22
EP3067355A4 (en) 2017-04-26
RU2016116501A3 (cg-RX-API-DMAC7.html) 2018-07-12
DK3067355T3 (da) 2021-01-04
CA3110803A1 (en) 2015-04-16
MY199066A (en) 2023-10-12
CN111153903A (zh) 2020-05-15
US10131665B2 (en) 2018-11-20
AR132030A2 (es) 2025-05-21
MX2016004506A (es) 2016-06-16
US20160272641A1 (en) 2016-09-22
JPWO2015053297A1 (ja) 2017-03-09
AR132029A2 (es) 2025-05-21
HUE051925T2 (hu) 2021-04-28
EP3613741A1 (en) 2020-02-26
IL289275A (en) 2022-02-01
BR112016006266A2 (cg-RX-API-DMAC7.html) 2017-08-22
BR122022016622B1 (pt) 2023-11-07
HK1250030A1 (en) 2018-11-23
KR20220054694A (ko) 2022-05-03
KR102487297B1 (ko) 2023-01-12
US11414417B2 (en) 2022-08-16
JP2020007366A (ja) 2020-01-16
NZ757220A (en) 2021-12-24
AR132028A2 (es) 2025-05-21
NZ757221A (en) 2021-12-24
RU2019115119A3 (cg-RX-API-DMAC7.html) 2022-04-26
RU2019115119A (ru) 2019-05-29
BR112016006266B1 (pt) 2022-11-16
TWI673269B (zh) 2019-10-01
JP6617029B2 (ja) 2019-12-04
ES2842225T3 (es) 2021-07-13
IL244969B (en) 2022-01-01

Similar Documents

Publication Publication Date Title
AR132028A2 (es) Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
BR112014026908A2 (pt) síntese direta de cu-sapo-34 com base na combinação de um complexo de cobre-poliamina e uma molécula orgânica adicional, e suas implicações catalíticas
PE20150282A1 (es) Nuevos compuestos bifuncionales utiles como ligando de uranios (vi), metodos de sintesis de los mismos y usos de los mismos
NZ718607A (en) Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines
JP2015532645A5 (cg-RX-API-DMAC7.html)
CO6700138A1 (es) Procedimiento de preparación de sal de l-arginina de perindoprilo
MX2016001096A (es) Sales de dasatinib en forma amorfa.
EP2902359A4 (en) STEAM CRACKING CATALYST, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR HYDROGEN SCRUBBING BY STEAM CRACKING
RU2017123112A (ru) Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированого препарата
MY165005A (en) Process for preparing and purifying salts of acrylamido-2-methylpropanesulfonic acid
MX2016001095A (es) Sales de dasatinib en forma cristalina.
RU2013144861A (ru) Способ синтеза нанокомпозита feco/c на основе полиакрилонитрила
TN2016000269A1 (en) Water soluble crystallin salts of certain harringtonines unambiguously protonated on their alkaloid nitrogen and their use as chemotherapeutic drugs.
BR112016006865A2 (pt) berberinas substituídas e suas sínteses
MX2013009598A (es) Composiciones que comprenden alquilalcoxisulfonatos para la produccion de espumas estables a alta temperatura.
FR3007424B1 (fr) Procede de fabrication d'acide formique par reduction electrocatalytique en phase gazeuse du co2
JP2013063896A5 (ja) アルカリ金属ケイ酸塩の合成方法
AR086310A1 (es) Solvente mejorado para la recuperacion de anhidrido maleico a partir de una corriente de gas
BR112016015130A2 (pt) Processos contínuos para preparar n-butanol
BR112022013216A2 (pt) Produção contínua de hidratos de clatrato a partir de correntes aquosas e formadoras de hidratos, métodos e usos dos mesmos.
AR107793A1 (es) Sistemas catalizadores selectivos y procedimiento para la producción de espinetoram
JO3276B1 (ar) طريقة لتخليق 3، 4-داي ميثوكسي باي سيكلو [4. 2. 0] أوكتا-5،3،1-تراي إين-7-كربونيتريل واستخدامها لتخليق ايفابرادين والأملاح المضافة منه مع حمض مقبول صيدلانيا.
BR112014029361A2 (pt) método de produção de ácido tereftálico e seus derivados
RU2013151044A (ru) Способ получения кобальтита лития
RU2011131637A (ru) Способ очистки от железа кислых растворов солей, содержащих нитрат алюминия

Legal Events

Date Code Title Description
FC Refusal